Navigation Links
AMT Receives Orphan Drug Designation From the U.S. Food and Drug Administration Duchenne Muscular Dystrophy Gene Therapy

AMT Receives Orphan Drug Designation From the U.S. Food and Drug Administration Duchenne... -- AMSTERDAM, September 24, 2010 /PRNewswire-FirstCall/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Clinical Trials & Medical Discoveries, FDA Approval Click to view news release full screen  

AMT Receives Orphan Drug Designation From the U.S. Food and Drug Administration Duchenne Muscular Dystrophy Gene Therapy


AMSTERDAM, September 24, 2010 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (AMT) Holding N.V. (Euronext: AMT), a leader in the field of human gene therapy, announced today that the U.S. Food and Drug Administration (FDA) has designated AMT-080, a gene therapy for Duchenne muscular dystrophy (DMD) as an orphan drug. In October 2009, the Committee for Orphan Medical Products of the European Medicines Agency granted AMT-080 orphan designation for the same indication in the European Union.

AMT has shown efficacy in studies of a preclinical model of DMD. These proof of concept studies demonstrated that AMT's technology resulted in functional dystrophin synthesis in both the heart and skeletal muscles, leading to the prevention of muscular dystrophy. These data are strengthened by a study in which this gene therapy approach was shown to successfully restore dystrophin activity in diseased human muscle cells obtained from biopsies of DMD patients. A Phase I/II clinical trial is scheduled to start by the end of 2012.

AMT has received an Innovation Credit of up to EUR 4 million from the Dutch government to support the development of AMT's gene therapy treatment for Duchenne Muscular Dystrophy (DMD). The credit is granted by SenterNovem, an agency of the Dutch Ministry of Economic affairs.

"It is exceptional that we have been able to reveal the promise of this therapy to the FDA in this early stage of the development. We believe our proven adenoassociated viral vector technology used in all our gene therapy products provides a distinct advantage. AMT has successfully conducted three clinical trials with its lead product Glybera that employs this technology, confirming that AAV-based delivery technology is safe and efficacious," noted Jörn Aldag, CEO of Amsterdam Molecular Therapeutics.

The FDA's orphan drug designation is intended to encourage research and development of new therapies for diseases that affect fewer than 200,000 U.S. residents. As a designated orphan drug, AMT-080 is eligible for tax credits based on its clinical development costs, as well as assistance from the FDA in guiding the drug through the regulatory approval process. The designation provides the opportunity for AMT-080 to obtain market exclusivity for seven years from the drug's marketing approval date.

About Duchenne Muscular Dystrophy

DMD is a severe disease characterized by progressive muscle degeneration. It affects young children, almost exclusively boys, and leads to progressive paralysis and death in young adulthood. The disease is caused by mutations in the dystrophin gene, as a result of which the production of functional dystrophin protein, an important structural component within muscle tissue, is blocked. Currently, there is no treatment to prevent the fatal outcome of this disease. DMD affects one in 3,500 males, making it one of the most prevalent of muscular dystrophies.

About Amsterdam Molecular Therapeutics (AMT) Holding N.V.

AMT, founded in 1998 and based in Amsterdam, is a leader in the development of human gene based therapies. Using AAV as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. This safe and efficacious proprietary platform offers a unique manufacturing capability which can be applied to a large number of rare (orphan) diseases that are caused by one faulty gene. Currently, AMT has a product pipeline with several AAV-based gene therapy products in LPLD, Hemophilia B, DMD, Acute Intermittent Porphyria and Parkinson's Disease at different stages of research or development.


Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of Amsterdam Molecular Therapeutics (AMT) Holding N.V. only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business, including, but not limited to, the timely commencement and success of AMT's clinical trials and research endeavors, delays in receiving U.S. Food and Drug Administration or other regulatory approvals (i.e. EMA, Health Canada), market acceptance of AMT's products, effectiveness of AMT's marketing and sales efforts, development of competing therapies and/or technologies, the terms of any future strategic alliances, the need for additional capital, the inability to obtain, or meet, conditions imposed for required governmental and regulatory approvals and consents. AMT expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. For a more detailed description of the risk factors and uncertainties affecting AMT, refer to the prospectus of AMT's initial public offering on June 20, 2007, and AMT's public announcements made from time to time.

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Professor Leroux From ETH Receives the Debiopharm Life Sciences Award 2010
2. NephRx Corp. Receives Orphan Drug Designation for NX001 for Prevention of Delayed Kidney Graft Function
3. MabVax Therapeutics Receives Small Business Innovation Research Program Award from the National Cancer Institute
4. NanoSmart™ Pharmaceuticals, Inc. Receives Patent Allowance for Tumor Targeting Platform Technology
5. Renhuang Receives AAA(1) Rating from Chinese Academy of International Trade & Economic Cooperation of Ministry of Commerce
6. Keck Graduate Institute Receives $3.6 Million NIH Grant
7. MacroGenics Receives NIH Grant Funding of $9.8M for Three Projects; Funding Further Advances DART Platform and Infectious Disease Portfolio
8. IIVS Receives First Mark Twain Ethical Science Award for Successes In Replacing Animals for Chemical and Product Safety Testing
9. Sirnaomics Receives Two SBIR Grants from NIH for Developing siRNA Therapeutics to Treat Glioblastoma and Influenza Infection
10. China Agritech, Inc. Receives $10 Million From Warrant Exercise by The Carlyle Group
11. Chiasma Receives Orphan Drug Designation From the FDA for Octreolin™ for the Oral Treatment of Acromegaly
Post Your Comments:
(Date:10/13/2015)... , October 13, 2015 the United ... Europe .  PRCC represents about 14% of all new cases ... , Canada and Europe ... kidney cancer.   --> Hutchison China MediTech Limited ("Chi-Med") ... R&D subsidiary, and AstraZeneca AB (publ) ("AstraZeneca") have completed enrolment in ...
(Date:10/12/2015)... , Oct. 12, 2015  Rebiotix Inc. ... (FDA) has designated its lead Microbiota Restoration Therapy ... treatment of recurrent Clostridium difficile (C ... infection that causes 29,000 deaths in the U.S. ... biotechnology company that was founded to revolutionize the ...
(Date:10/12/2015)... , October 12, 2015 ... Dario™ Diabetes Management Solution, today announced its Medical Director, ... case study at MobiHealth,s 5th EAI International Conference ... "Transforming healthcare through innovations in mobile and wireless technologies," ... England from October 14 - 16, 2015. ...
(Date:10/12/2015)... CA (PRWEB) , ... October 12, 2015 , ... ... announced the launch of LifeTrak Zoom, the world’s first amphibious fitness tracker that seeks ... that offers flexwear technology and accurate heart rate monitoring both in water ...
Breaking Biology Technology:
(Date:9/30/2015)... -- The global glucose monitoring device and diabetes management market is ... report on the industry from Kalorama Information. Sales in the traditional ... by continuous glucose monitoring and sensor segment, according to the ... products in its latest report, The Global Glucose Monitoring ... , ...
(Date:9/28/2015)... -- The global image sensors market ... by 2020, growing at a CAGR of 4.6% from ... (BSI) technique to improve picture quality are expected to ...      (Logo: , The light falls ... and, thus, reduce the noise interference and increase picture ...
(Date:9/24/2015)... LONDON , September 24, 2015 /PRNewswire/ ... 00.01 25 september 2015 Kerv ... inom digitala finanstjänster, lanserar idag världens första ... att samla in 77 000 GBP för ... ) , ...
Breaking Biology News(10 mins):